Discounted Cash Flow
Centessa Pharmaceuticals Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $0 | $-10.7m | $-10.6m | — | — |
| 2021 | $0 | $-381.1m (-3473.8%) | $-135.3m (-1172.8%) | — | $-5.07 |
| 2022 | $0 | $-216.2m (43.3%) | $-201.7m (-49.1%) | — | $-2.31 (54.4%) |
| 2023 | $6.9m | $-151.1m (30.1%) | $-160.5m (20.4%) | -2204.7% | $-1.57 (32.0%) |
| 2024 | $3.9m (-42.7%) | $-235.8m (-56.0%) | $-34.0k (100.0%) | -6005.0% (-172.4%) | $-2.06 (-31.2%) |
| 2025 | $15.0m (282.1%) | $-197.5m (16.2%) | $-194.2m (-571041.2%) | -1316.9% (78.1%) | $-1.46 (29.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.